Zhou et al., 2023 [71] observed high concordance between the SP263 and 22C3 assays for PD-L1 expression, with both predicting the efficacy of adjuvant atezolizumab in early NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.